Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05414253
Active, not recruiting Not applicable

Chlorhexidine Plus Hyaluronic Acid Mouthwash in Surgical Wound Healing Following Third Molar Surgery

NCT05414253 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Pisa
Phase
Not applicable
Started
2022-06-01
Last updated
2026-04-08

Condition(s) studied

Wound HealSurgical WoundImpacted Third Molar Tooth

Investigational drug(s) / intervention(s)

Parallel Assignment

Parallel Assignment: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up

Study summary

Evaluation of the response of gingival tissues to the use of mouthwash with chlorhexidine and chlorhexidine + hyaluronic acid in terms of healing of the surgical wound following third molar surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * males or females of age range between 18 and 70 years, * good health status, * indication to perform third molar surgery, * patients willing to give informed consent, * compliance to the study follow-up, Exclusion Criteria: * pregnancy or breast-feeding, * indication to antibiotic therapy prior to surgical treatment, * chronic infections, * systemic diseases (including cardiovascular, pulmonary, cerebral, and metabolic diseases), * previous therapy with the mouth rinses employed in the present study, and * smoking habit (\>20 cigarettes per day, and/or pipe or cigar smoking).

Primary outcome measure(s)

  • Wound Healing Index (WHI) (Wachtel classification) — Measured at day 3, day 7, and day 14
    Changes in WHI, measured orally through clinical examination on all the incisions, assigning a score from 1 to 5. Score 1: complete wound healing: absence of fibrin line in the interproximal area Score 2: complete wound healing: presence of a thin fibrin line in the interproximal area Score 3: complete wound healing: presence of fibrin clot in the interproximal area Score 4: incomplete wound healing: presence of partial necrosis of the interproximal area Score 5: incomplete wound healing: total necrosis of the interproximal area

Trial sites (1)

FacilityCityRegionStatus
University Hospital of Pisa Pisa Italy

More University of Pisa trials in Italy

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients Recruiting
Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix Active, not recruiting
Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues Recruiting
Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients Recruiting
Evaluation of a Multimodal Tactile Feedback System for Upper Limb-loss Users: Embodiment and Performance Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05414253 on ClinicalTrials.gov ↗ ← All trials in Italy